Tag: Scil Technology

Company News: Nanohale AG acquires R&D and service units of Scil Technology GmbH

– Transaction creates new Nanohale subsidiary named Formycon GmbH –

Scil Technology GmbH and Nanohale AG today announced that Nanohale has acquired the entire R&D, contract development and manufacturing organization of Scil Technology GmbH in an asset deal, effective December 31, 2011. Employees and inventory of Scil Technology GmbH have become part of Formycon GmbH, a fully-owned subsidiary of Nanohale AG. The rights to the tissue regeneration projects, which were out-licensed by Scil Technology to Medtronic, Inc. and Sanofi, will remain with Scil Technology GmbH, which will be sustained as an independent company to manage its existing collaborations. Financial details have not been disclosed.

Scil Technology recently out-licensed its cartilage regeneration program for the treatment of osteoarthritis and osteochondral defects to Sanofi. The company has strong expertise in protein drug development, formulation and analytics, which is highly complementary to Nanohale´s existing protein formulation platform and will enable Nanohale to strengthen its biopharmaceutical development expertise.

Christian Nafe, CEO of Scil Technology, who was responsible for the transaction together with Klaus Binder (COO), said that the agreement creates an excellent exit opportunity for Scil Technology´s investors at BioNet Holding.

Company News: Sanofi Licenses Worldwide Rights on Regenerative Treatment for Osteoarthritis and Cartilage Disorders from Scil Technology

Scil Technology GmbH, a privately held biopharmaceutical company with core expertise in protein drug development, formulation and analytics, today announced that Sanofi (EURONEXT: SAN and NYSE: SNY) has exclusively licensed Scil Technology’s program for the regenerative treatment of osteoarthritis and cartilage disorders.

Under the agreement, SCIL Technology will receive an upfront payment and potential milestone payments totaling up to EUR 180 million. Moreover, the company is entitled to receive undisclosed royalties on worldwide product sales. Sanofi will assume responsibility for the progression of the development program with immediate effect, including the start of clinical trials.

The program is based on targets for the regeneration of cartilage tissue, which also stimulate chondrocyte differentiation and the synthesis of cartilage matrix. The leading compound is based on a proprietary formulation for direct delivery into the joint, making it an excellent treatment option for osteoarthritis. The program is currently in advanced preclinical development.

The cartilage regenerative program is Scil Technology’s second program which has been out-licensed successfully. The first (GDF-5) was taken over by Medtronic after completion of Phase II.

Company News: Scil Technology Establishes Independent Service Unit formycon

Scil Technology GmbH, a biopharmaceutical company with core expertise in protein drug development, formulation and analytics, today announced the establishment of an independent service unit named formycon. formycon offers services for external customers focusing on formulation development, drug product manufacturing and process development, as well as quality control and analytics. Scil Technology’s long-standing track record in protein development enables formycon to support its customers with key activities such as protein characterization, preformulation, formulation development and drug product production as well as analytics under GMP and non-GMP conditions (including analytical method development).

In addition to liquid and freeze dried formulations, formycon also offers liposomal and specialty formulations, e.g. for topical and local administration – an area which distinguishes formycon from most other service providers worldwide. Therefore, formycon´s core strengths lie in the combination of a broad range of formulation types with comprehensive knowledge of regulatory processes and excellent analytics according to GMP standards and the requirements outlined by the ICH and pharmacopoeias.

formycon is operating on a fee for service basis and employs a staff of 20. The unit is licensed and GMP-certified as an analytical laboratory.

Company News: Scil Technology Receives Public Research Grant for Novel Rheumatoid Arthritis Treatments

Scil Technology GmbH, a biopharmaceutical company with core expertise in protein drug development, formulation and analytics, today announced that it has been awarded research funding by the German Federal Ministry of Education and Research (BMBF) under BMBF’s KMU-innovativ scheme. The EUR 0.9 million grant supports Scil Technology’s research program to explore the therapeutic potential of repellent proteins for the treatment of rheumatoid arthritis (RA).

The course of RA is affected by the destruction of cartilage tissue and inflammation of the joints. Recently, it has been published that so-called repellent proteins inhibit fundamental processes relevant for the development of the disease. Repellent proteins therefore bear the potential to provide the first causative treatment of RA.

1 2